Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors

- Extensive Track Record in U.S. and Global Product Launches and Supply Chain Management -

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Christine Ann Miller to its Board of Directors, effective immediately. A global pharmaceutical veteran with more than 20 years of experience in life sciences, Ms. Miller is President and Chief Executive Officer of Melinta Therapeutics LLC, a company focused on the development and commercialization of innovative therapies for acute and life-threatening illnesses.

“We are excited to welcome Christine, a highly-qualified executive in the life-science industry, to our Board of Directors,” stated Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “Christine’s leadership, commercial and supply chain management experience and commitment to patients will serve us well as we prepare for a potential launch of Zimura^® (avacincaptad pegol) in geographic atrophy secondary to age-related macular degeneration. We believe the addition of Christine to our Board of Directors is part of our continued commitment to build a strong Board of Directors that can guide the growth of the Company and best represent our shareholders.”

“I am thrilled to join the impressive Iveric Bio board and to have the opportunity to work with a highly-dedicated executive team at this pivotal time,” stated Ms. Miller. “I look forward to contributing my insight and expertise to a Company that is committed to delivering treatments for debilitating retina diseases and having a positive impact on patients’ lives.”

Prior to her role at Melinta Therapeutics, where she also serves on the Board of Directors, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis, where she was responsible for transitioning the portfolio toward rapid-growth and higher-margin segments such as complex generics and value-added medicines, while continuing to build the branded generics business. Her achievements at Sandoz included directing more than 50 product launches that generated over $300 million of new annual revenue, closing numerous business development acquisitions, and building a robust five-year development and acquisition product pipeline.

In addition to her work at Sandoz, Ms. Miller spent over a decade at Actavis (now Allergan) and its predecessor Watson Pharmaceuticals, where she led the preparation of numerous product launches and held leadership roles in both R&D operations and supply chain management. She began her career as a chemical engineer and procurement analyst at Merck.

Ms. Miller earned an MBA and a Master’s in Technology Management at Stevens Institute of Technology and a BS in Chemical Engineering from Rensselaer Polytechnic Institute.

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retina diseases including all stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Iveric Bio Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, the Company’s forward looking statements include statements about its expectations regarding its development and regulatory strategy for Zimura and its other product candidates, including its plans to seek regulatory approval for and, if approved, commercialize Zimura, and the Company’s strategy to develop and commercialize treatments for debilitating retina diseases . Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the progression and duration of the COVID-19 pandemic and responsive measures thereto and related effects on the Company’s research and development programs, operations and financial position, expectations for regulatory matters, the initiation and the progress of research and development programs and clinical trials, including enrollment and retention in clinical trials, availability of data from these programs, reliance on clinical trial sites, contract development and manufacturing organizations and other third parties, establishment of manufacturing capabilities, developments from the Company’s competitors and the marketplace for the Company’s products, human capital matters, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments may cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005924/en/